Soluble pathfinding capsule as well as preparation method and application thereof

By designing soluble pathfinder capsules, using specific materials and proportional relationships, it can be discharged within 30 hours when the intestine is unobstructed and disintegrated within 30 to 72 hours when there is obstruction, solving the problem of retention of pathfinder capsules and judging intestinal suitability. , ensuring the safety and effectiveness of the inspection.

CN119055219APending Publication Date: 2024-12-03CHONGQING JINSHAN SCI & TECH GRP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411273141.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing trail capsules are prone to retention in the case of intestinal stenosis, resulting in pain and medical disputes between patients. The non-degradable wireless radio frequency sensors have a risk of retention, and lack a capsule endoscopy that can accurately judge the suitability and safety of the intestinal tract. Method of checking.

Method used

A soluble pathfinder capsule is designed, consisting of the first disintegration, the second disintegration and the capsule coating, using a specific proportion of anhydrous lactose, starch, talc, crosslinked polyvinylpyrrolidone, tartaric acid, sodium bicarbonate Materials such as barium sulfate regulate the disintegration time. If the intestine is unobstructed, it will be discharged within 30 hours. If there is obstruction, it will be completely disintegrated within 30~72 hours. To judge the intestinal condition and avoid retention.

Benefits of technology

It is achieved to safely and accurately determine whether the intestinal tract is suitable for examination without losing the opportunity for capsule endoscopy, avoiding the retention of the pathfinder capsule, and reducing the patient's pain and medical risks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure SMS_1
    Figure SMS_1
Patent Text Reader

Abstract

The invention provides a soluble pathfinding capsule which is composed of a first disintegrating body, a second disintegrating body and a capsule coating, and the first disintegrating body is composed of a first capsule layer and a second capsule layer; the raw materials of the first capsule layer comprise anhydrous lactose, starch, talcum powder and cross-linked polyvinylpyrrolidone according to a specific proportion; the raw materials of the second capsule layer comprise anhydrous lactose, starch, talcum powder and cross-linked polyvinylpyrrolidone according to a specific proportion; the second disintegrating body is prepared from the following raw materials in a specific proportion: anhydrous lactose, starch, talcum powder, tartaric acid, sodium bicarbonate and barium sulfate. The invention further provides a preparation method and application of the soluble pathfinding capsule. The soluble pathfinding capsule provided by the invention can be completely dissolved in a human body without a retention risk; the structure is simple, and production and processing are easy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices and capsule endoscopes, and in particular to a soluble pathfinder capsule, a preparation method and application thereof. Background Art

[0002] In the process of medical diagnosis, capsule endoscopy has been widely used and recognized by medical staff and patients due to its advantages of being painless, easy to tolerate, easy to operate, and non-invasive. The commonly used medical material in this examination is the pathfinder capsule. However, in the clinical examination of capsule endoscopy, doctors found that some patients may have the risk of pathfinder capsules being retained in the body due to intestinal stenosis caused by tumors or various diseases. The existing conventional pathfinder capsules are not degradable. If the capsule is retained in the body, it must be removed, otherwise it will lead to serious consequences; and unlike the stomach and colon, the small intestine has a special anatomical position. After the capsule is retained, it is difficult to remove it from the small intestine, and sometimes even requires laparotomy, which brings great pain to the patient and even causes medical disputes. Therefore, a method is needed to accurately judge whether the intestinal conditions are suitable for capsule endoscopy; this method is not only non-invasive, safe, but also reliable, and neither allows patients to undergo unnecessary examinations or operations, nor does it allow patients to lose the opportunity to use capsule endoscopy to examine diseases.

[0003] The pathfinder capsule in the prior art consists of two parts: a capsule body and a radio detector. The capsule body is exactly the same in shape and size as a gastrointestinal capsule endoscope, and is mainly made of degradable lactose material. It contains barium and radio frequency sensors that can be developed under X-rays, but does not contain the same lenses and electronic components as the gastrointestinal capsule endoscope. This pathfinder capsule has time indicators at both ends. When it encounters a narrow part in the body and is trapped, the time indicator of the capsule body can be dissolved by the digestive fluid, thereby degrading the entire capsule body. However, the above-mentioned pathfinder capsule contains a radio frequency sensor and a barium developer. Most of the radio frequency sensors are non-degradable electronic devices, and there is still a certain risk of retention after entering the human body.

[0004] In view of the above, it is of great significance to provide a pathfinder capsule that is both degradable and can accurately reflect whether the intestine is suitable for capsule endoscopy. Summary of the invention

[0005] The technical problem solved by the present invention is to provide a soluble pathfinder capsule. The soluble pathfinder capsule provided by the present application can accurately judge the intestinal conditions and can be degraded.

[0006] In view of this, the present application provides a soluble pathfinder capsule, which is composed of a first disintegrating body, a second disintegrating body and a capsule coating; the second disintegrating body is a solid capsule body, the first disintegrating body is coated on the surface of the second disintegrating body, and the capsule coating is coated on the surface of the first disintegrating body;

[0007] The first disintegrating body is composed of a first capsule layer near the capsule coating end and a second capsule layer far from the capsule coating end;

[0008] The raw materials of the first capsule layer include: 50-65wt% anhydrous lactose, 20-40wt% starch, 2-10wt% talc, and 2-5wt% cross-linked polyvinyl pyrrolidone;

[0009] The raw materials of the second capsule layer include: 60-70wt% anhydrous lactose, 10-15wt% starch, 2-10wt% talc, and 10-15wt% cross-linked polyvinyl pyrrolidone;

[0010] The raw materials of the second disintegrating body include: 50-60wt% of anhydrous lactose, 5%-10wt% of starch, 2-5wt% of talc, 10-15wt% of tartaric acid, 10-15wt% of sodium bicarbonate, and 10-15wt% of barium sulfate.

[0011] Preferably, the thickness of the first disintegrating body is 2-4 mm, the thickness of the capsule coating is 0.1-1 mm, and the thickness of the second disintegrating body is 3-5 mm; the thickness ratio of the first capsule layer to the second capsule layer in the first disintegrating body is 1:(2-5).

[0012] Preferably, the density of the first disintegrated body is 1-1.5 g / cm 3 The density of the second disintegrated body is 1.2-1.6 g / cm 3 .

[0013] Preferably, the raw materials of the capsule coating include one or more of hydroxypropyl methylcellulose, gelatin and mannitol.

[0014] Preferably, the first disintegrating body consists of two hollow half capsules.

[0015] The present application also provides a method for preparing the soluble pathfinder capsule, comprising the following steps:

[0016] 50-65wt% of anhydrous lactose, 20-40wt% of starch, 2-10wt% of talc and 2-5wt% of cross-linked polyvinyl pyrrolidone are mixed and placed in a hollow mold, and pressed to obtain a first capsule layer;

[0017] 60-70 wt% of anhydrous lactose, 10-15 wt% of starch, 2-10 wt% of talc and 10-15 wt% of cross-linked polyvinyl pyrrolidone are mixed and placed in a hollow mold, and pressed to obtain a second capsule layer;

[0018] combining the first capsule layer and the second capsule layer to obtain a first disintegrated body;

[0019] 50-60wt% of anhydrous lactose, 5%-10wt% of starch, 2-5wt% of talc, 10-15wt% of tartaric acid, 10-15wt% of sodium bicarbonate and 10-15wt% of barium sulfate are mixed and filled into a mold, and pressed to obtain a second disintegrating body;

[0020] placing the second disintegrating body in the first disintegrating body, with the second capsule layer of the first disintegrating body close to the end of the second disintegrating body, to obtain a solid capsule body;

[0021] The solid capsule body is placed in a capsule coating to obtain a soluble pathfinder capsule.

[0022] Preferably, in the step of preparing the first capsule layer, the pressing pressure is 1-3T, and the holding time is 1-5min;

[0023] In the step of preparing the second capsule layer, the pressing pressure is 1-3T, and the holding time is 1-5min;

[0024] In the step of preparing the second disintegrated body, the pressing pressure is 1-3T, and the holding time is 1-5min.

[0025] The present application also provides the use of a soluble pathfinder capsule in determining intestinal obstruction conditions, wherein the soluble pathfinder capsule is the soluble pathfinder capsule or the soluble pathfinder capsule prepared by the preparation method.

[0026] Preferably, the application is specifically:

[0027] Administer the soluble pathfinder capsule and observe whether the soluble pathfinder capsule is completely discharged within 30 hours;

[0028] If so, capsule endoscopy is appropriate;

[0029] If not, capsule endoscopy is not appropriate.

[0030] Preferably, the application is specifically:

[0031] Administer the soluble pathfinder capsule and observe whether the soluble pathfinder capsule is completely discharged within 30 hours;

[0032] If so, capsule endoscopy is appropriate;

[0033] If it is uncertain whether the soluble pathfinder capsule has been expelled, an X-ray or CT examination should be performed ≤30 hours after the administration of the soluble pathfinder capsule. If the capsule is confirmed to be completely expelled based on the contrast image, capsule endoscopy is appropriate.

[0034] If an X-ray or CT scan is performed when the soluble pathfinder capsule has been administered for more than 30 hours and it is determined based on the contrast images that the capsule has not been expelled, capsule endoscopy is not suitable.

[0035] The present application provides a soluble pathfinder capsule, which is composed of a first disintegrating body, a second disintegrating body and a capsule coating, wherein the first disintegrating body is composed of a first capsule layer and a second capsule layer, the raw materials of the first capsule layer include anhydrous lactose, starch, talc and cross-linked polyvinyl pyrrolidone in a specific proportion, the raw materials of the second capsule layer include anhydrous lactose, starch, talc and cross-linked polyvinyl pyrrolidone in a specific proportion, and the raw materials of the second disintegrating body include anhydrous lactose, starch, talc, tartaric acid, sodium bicarbonate and barium sulfate in a specific proportion. The present application provides a soluble pathfinder capsule, which can be discharged in less than 30 hours under the condition of unobstructed intestines by regulating the ratio of the raw materials in the first disintegrating body and the second disintegrating body. If it is not discharged within 30 hours, there is a situation of intestinal obstruction and stenosis, thereby accurately judging whether the intestine can be subjected to capsule endoscopy, and the raw materials of the pathfinder capsule are degradable materials, and there will be no problem of intestinal retention. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 The schematic diagram of the structure of the soluble pathfinder capsule of the present invention, 1 is the capsule coating, 2 is the first disintegrating body, and 3 is the second disintegrating body;

[0037] Figure 2 The figure is a schematic diagram of the application process of the soluble pathfinder capsule of the present invention. DETAILED DESCRIPTION

[0038] In order to further understand the present invention, preferred embodiments of the present invention are described below in conjunction with examples. However, it should be understood that these descriptions are only for further illustrating the features and advantages of the present invention, rather than limiting the claims of the present invention.

[0039] In view of the requirement for pathfinder capsules in the prior art to judge the patency of the intestine and the performance of degradability, the present application provides a soluble pathfinder capsule, which includes a first disintegrating body, a second disintegrating body and a capsule coating, and limits the raw materials and the proportion relationship of the first disintegrating body and the second disintegrating body. On this basis, if the gastrointestinal tract is unobstructed, it can be discharged within 30 hours. If the gastrointestinal tract is obstructed, stenosis, etc. occurs, it will completely disintegrate within 30 to 72 hours, which not only realizes the judgment of the gastrointestinal tract condition but also avoids the risk of the pathfinder capsule being retained in the body. Specifically, an embodiment of the present invention discloses a soluble pathfinder capsule, which is composed of a first disintegrating body, a second disintegrating body and a capsule coating, such as Figure 1 As shown; the second disintegrating body is a solid capsule body, the first disintegrating body is coated on the surface of the second disintegrating body, and the capsule coating is coated on the surface of the first disintegrating body;

[0040] The first disintegrating body is composed of a first capsule layer near the capsule coating end and a second capsule layer far from the capsule coating end;

[0041] The raw materials of the first capsule layer include: 50-65wt% anhydrous lactose, 20-40wt% starch, 2-10wt% talc, and 2-5wt% cross-linked polyvinyl pyrrolidone;

[0042] The raw materials of the second capsule layer include: 60-70wt% anhydrous lactose, 10-15wt% starch, 2-10wt% talc, and 10-15wt% cross-linked polyvinyl pyrrolidone;

[0043] The raw materials of the second disintegrating body include: 50-60wt% of anhydrous lactose, 5%-10wt% of starch, 2-5wt% of talc, 10-15wt% of tartaric acid, 10-15wt% of sodium bicarbonate, and 10-15wt% of barium sulfate.

[0044] In the soluble pathfinder capsule provided in the present application, the capsule coating is coated on the surface of the first disintegrating body, and the capsule coating is composed of one or more gastric soluble materials, specifically including one or more of hydroxypropyl methylcellulose, gelatin and mannitol.

[0045] The first disintegrating body is in the shape of a hollow capsule, which can be composed of two identical hollow half capsules. The first disintegrating body is composed of a first capsule layer near the capsule coating end and a second capsule layer far from the capsule coating end, wherein the starch content in the first capsule layer is slightly higher and the cross-linked polyvinyl pyrrolidone content is slightly lower, so that the disintegration speed of the first disintegrating body in the outer part is very slow, and is expected to be set at ≥30h; the starch content in the second capsule layer is slightly lower and the cross-linked polyvinyl pyrrolidone content is slightly higher, so that the disintegration speed of the second capsule layer is slightly faster than the disintegration speed of the first capsule layer, and the disintegration time of the second disintegrating body is ≤30h. Therefore, the first disintegrating body has a timing effect. In the raw materials of the first capsule layer, the content of anhydrous lactose is 50-65wt%, specifically, the content of anhydrous lactose is 52-62wt%; for example, the content of anhydrous lactose in the present application is 51wt%, 53wt%, 54wt%, 55wt%, 56wt%, 57wt%, 59wt%, 60wt%, 61wt%, 63wt%, 64wt%, and other values ​​within the range are also possible. The content of starch is 20-40wt%, specifically, the content of starch is 23-37wt%; for example, the content of starch in the present application is 21wt%, 24wt%, 25wt%, 26wt%, 27wt%, 28wt%, 29wt%, 30wt%, 31wt%, 32wt%, 33wt%, 34wt%, 35wt%, 36wt%, 38wt%, 39wt%, and other values ​​within the range are also possible. The content of the talc is 2-10wt%, specifically, the content of the talc is 3-8wt%; for example, the content of the talc in the present application is 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, 9wt%, and other values ​​within the range are also acceptable. The content of the cross-linked polyvinyl pyrrolidone is 2-5wt%, for example, the content of the cross-linked polyvinyl pyrrolidone in the present application is 2wt%, 3wt%, 4wt% or 5wt%, and other values ​​within the range are also acceptable.

[0046] In the raw materials of the second capsule layer, the content of anhydrous lactose is 60-70wt%, specifically, the content of anhydrous lactose is 62-67wt%; for example, the content of anhydrous lactose in the present application is 61wt%, 63wt%, 64wt%, 65wt%, 66wt%, 68wt%, 69wt%, and other values ​​within the range are also possible. The content of starch is 10-15wt%, specifically, the content of starch is 11-14wt%; for example, the content of starch in the present application is 12wt%, 13wt%, and other values ​​within the range are also possible. The content of talcum powder is 2-10wt%, specifically, the content of talcum powder is 3-8wt%; for example, the content of talcum powder in the present application is 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, 9wt%, and other values ​​within the range are also possible. The content of the cross-linked polyvinyl pyrrolidone is 10-15wt%, specifically, the content of the cross-linked polyvinyl pyrrolidone is 11-14wt%; for example, the content of polyvinyl pyrrolidone in the present application is 12wt%, 13wt%, and other point values ​​within the range are also acceptable. In the first disintegrating body, anhydrous lactose is the main filler, and starch is used as a binder. Mixing with anhydrous lactose can increase the overall viscosity, especially after absorbing water. The more starch content, the greater the viscosity of the capsule after absorbing water, and the slower the disintegration rate; talcum powder is used as a lubricant to make the capsule easier to form during the tableting process. Cross-linked polyvinyl pyrrolidone is used as a disintegrant for the capsule. It has strong swelling after absorbing water, and the first disintegrating body is easier to disintegrate after swelling. Therefore, the higher its content, the faster the disintegration rate.

[0047] Therefore, in the first disintegrating body of the present application, the ratio of different raw materials is adjusted to obtain disintegrating bodies with different disintegration times; the first disintegrating body completely disintegrates within 30 to 72 hours, and the second disintegrating body is exposed to the digestive fluid.

[0048] Furthermore, the greater the density of the first disintegrating body, the more compact the disintegrating body, the smaller the air gap between the raw materials, the slower the disintegration speed, and vice versa, the faster the disintegration speed; in the present application, the density of the first disintegrating body is 1-1.5 g / cm 3 Specifically, the density of the first disintegrated body is 1.2-1.4 g / cm 3 The thickness of the first disintegrating body is 2-4 mm; the thickness ratio of the first capsule layer to the second capsule layer in the first disintegrating body is 1:(2-5), and specifically, the thickness ratio of the first capsule layer to the second capsule layer is 1:(3-4).

[0049] In the present application, the first disintegrating body is coated on the surface of the second disintegrating body, and the second disintegrating body is a solid capsule. In addition to anhydrous lactose, starch, and talcum powder, the raw materials of the second disintegrating body also contain tartaric acid, sodium bicarbonate, and barium sulfate; wherein the combination of tartaric acid and sodium bicarbonate is often used as an effervescent agent, and a chemical reaction will occur after contact with water to produce carbon dioxide, which can make the second disintegrating body disintegrate faster, and the higher the content of the two components, the faster the disintegration speed; and the speed of the second disintegrating body is much faster than that of the first disintegrating body, and complete disintegration can be achieved within 1 hour; barium sulfate is used as a contrast agent for capsule detection. In the second disintegrating body, the content of anhydrous lactose is 50~60wt%, specifically, the content of anhydrous lactose is 52~58wt%; for example, the content of anhydrous lactose in the present application is 51wt%, 53wt%, 54wt%, 55wt%, 56wt%, 57wt%, 59wt%, and other point values ​​within the range are also acceptable. The content of starch is 5-10wt%, specifically, the content of starch is 6-8wt%; for example, the content of starch in the present application is 7wt%, 9wt%, and other values ​​within the range are also acceptable. The content of talcum powder is 2-5wt%, for example, the content of talcum powder is 3wt%, 4wt%, and other values ​​within the range are also acceptable. The content of tartaric acid is 10-15wt%, specifically, the content of tartaric acid is 11-14wt%; for example, the content of tartaric acid in the present application is 12wt%, 13wt%, and other values ​​within the range are also acceptable. The content of sodium bicarbonate is 10-15wt%, specifically, the content of sodium bicarbonate is 11-14wt%; for example, the content of sodium bicarbonate in the present application is 12wt%, 13wt%, and other values ​​within the range are also acceptable. The content of barium sulfate is 10-15wt%, specifically, the content of barium sulfate is 11-14wt%. For example, the content of barium sulfate in the present application is 12wt%, 13wt%, and other values ​​within the range are also acceptable.

[0050] In the present application, the density of the second disintegrated body is 1.2-1.6 g / cm 3 Specifically, the density of the second disintegrated body is 1.3-1.5 g / cm 3 ;Thickness is 3~5mm.

[0051] In summary, the first disintegrating body can achieve complete disintegration in 30-72 hours, and the second disintegrating body is exposed to the digestive fluid, and the second disintegrating body disintegrates and completely disintegrates within 1 hour.

[0052] The present application also provides a method for preparing a soluble pathfinder capsule, comprising the following steps:

[0053] 50-65wt% of anhydrous lactose, 20-40wt% of starch, 2-10wt% of talc and 2-5wt% of cross-linked polyvinyl pyrrolidone are mixed and placed in a hollow mold, and pressed to obtain a first capsule layer;

[0054] 60-70 wt% of anhydrous lactose, 10-15 wt% of starch, 2-10 wt% of talc and 10-15 wt% of cross-linked polyvinyl pyrrolidone are mixed and placed in a hollow mold, and pressed to obtain a second capsule layer;

[0055] combining the first capsule layer and the second capsule layer to obtain a first disintegrated body;

[0056] 50-60wt% of anhydrous lactose, 5%-10wt% of starch, 2-5wt% of talc, 10-15wt% of tartaric acid, 10-15wt% of sodium bicarbonate and 10-15wt% of barium sulfate are mixed and filled into a mold, and pressed to obtain a second disintegrating body;

[0057] Placing the second disintegrating body in the hollow part of the first disintegrating body, with the second capsule layer of the first disintegrating body close to the end of the second disintegrating body, to obtain a solid capsule body;

[0058] The solid capsule body is placed in a capsule coating to obtain a soluble pathfinder capsule.

[0059] In the step of preparing the first capsule layer, the pressing pressure is 1-3T, and the holding time is 1-5min; in the step of preparing the second capsule layer, the pressing pressure is 1-3T, and the holding time is 1-5min.

[0060] In the step of preparing the second disintegrated body, the pressing pressure is 1-3T, and the holding time is 1-5min.

[0061] After the second disintegrating body is placed on the first disintegrating body, an adhesive is applied to the connection of the first disintegrating body to achieve the connection of the first disintegrating body; the adhesive is an adhesive well known to those skilled in the art, and this application does not impose any particular limitation on this.

[0062] The present application also provides the use of a soluble pathfinder capsule in determining intestinal obstruction conditions, wherein the soluble pathfinder capsule is the soluble pathfinder capsule described in the above scheme.

[0063] The specific application process of the soluble pathfinder capsule is as follows:

[0064] Administer the soluble pathfinder capsule and observe whether the soluble pathfinder capsule is completely discharged within 30 hours;

[0065] If so, capsule endoscopy is appropriate;

[0066] If not, capsule endoscopy is not appropriate.

[0067] Furthermore, the application is specifically as follows Figure 2 As shown, specifically:

[0068] Administer the soluble pathfinder capsule and observe whether the soluble pathfinder capsule is completely discharged within 30 hours;

[0069] If so, capsule endoscopy is appropriate;

[0070] If it is uncertain whether the soluble pathfinder capsule has been expelled, an X-ray or CT scan should be performed close to but no later than 30 hours after the administration of the soluble pathfinder capsule. If the capsule has been completely expelled based on the contrast image, capsule endoscopy is appropriate.

[0071] If the soluble pathfinder capsule is administered for more than 30 hours and an X-ray or CT scan is performed, and it is determined based on the contrast image that the capsule has not been expelled, then capsule endoscopy is not suitable.

[0072] In the present application, after the soluble pathfinder capsule is swallowed into the body, the capsule coating of the soluble pathfinder capsule first contacts the digestive fluid, and the coating can be completely dissolved in the stomach, and then the first disintegrating body is exposed to the digestive fluid, and the first disintegrating body begins to disintegrate. The first disintegrating body is partially dissolved within 30 hours of contact with the digestive fluid, but can still maintain a complete capsule shape, and does not allow the second disintegrating body to leak into the digestive fluid. Within 30h to 72h of contact between the capsule and the digestive fluid, the first disintegrating body is completely disintegrated; the second disintegrating body is exposed to the digestive fluid, and the second disintegrating body begins to disintegrate. The second disintegrating body is completely disintegrated within 1 hour of contact with the digestive fluid.

[0073] The basis for using the above-mentioned soluble pathfinder capsule to judge whether the patient's gastrointestinal tract is unobstructed is: when the patient's gastrointestinal tract is unobstructed, the pathfinder capsule will be excreted from the body within 30 hours, at this time the capsule is still in the shape of a capsule, the first disintegrating body is partially disintegrated, the second disintegrating body is intact, and the patient undergoes X-ray or CT examination, and there is no contrast agent remaining in the body; when the patient has gastrointestinal obstruction or stenosis, the pathfinder capsule will get stuck in the gastrointestinal tract, and the retention time of the capsule in the patient's body will exceed 30 hours. At this time, when the patient undergoes X-ray or CT examination again, the contrast agent in the second disintegrating body will be detected. Therefore, 30 hours after the pathfinder capsule test, when the patient undergoes X-ray or CT examination and finds the pathfinder capsule contrast image, it can be determined that the patient has gastrointestinal obstruction, stenosis, etc., and it is not appropriate to perform capsule endoscopy.

[0074] In order to further understand the present invention, the soluble pathfinder capsule and the preparation method thereof provided by the present invention are described in detail below in conjunction with the embodiments. The protection scope of the present invention is not limited by the following embodiments.

[0075] Example 1

[0076] (1) Weigh 0.25 g of anhydrous lactose, starch, talc, tartaric acid, sodium bicarbonate, and barium sulfate in a mass ratio of 50:10:5:12:12:11, mix them, and put them into a capsule-shaped mold of a tablet press. The capsule-shaped size is: diameter 4 mm, length: 12 mm. Under a pressure of 1 T, maintain the pressure for 2 minutes, open the mold, and take out the compressed capsule-shaped second disintegrated body. The density is 1.37 g / cm 3 ;

[0077] (2) Weighing anhydrous lactose, starch, talc, and cross-linked polyvinyl pyrrolidone with a total mass of 0.43 g and a mass ratio of 55:30:10:5, and putting them into a hollow semi-capsule-shaped mold of a tablet press, using a press to control the capsule thickness to 1 mm, and maintaining the pressure for 2 minutes under a pressure of 1 T to obtain a semi-hollow capsule part of the first capsule layer;

[0078] (3) Weigh 0.58 g of anhydrous lactose, starch, talc, and cross-linked polyvinyl pyrrolidone in a mass ratio of 65:15:10:10 and put them into the mold of the compressed step (2). Replace another press with one that controls the capsule thickness to 4 mm. Keep the pressure at 1 T for 2 minutes to obtain a semi-hollow capsule portion of the first disintegrated body of the combined portion of the first capsule layer and the second capsule layer. The density is 1.24 g / cm 3 , and the thickness ratio of the first capsule layer to the second capsule layer is 1:3;

[0079] (4) Repeat steps (2) to (3) to obtain two semi-hollow capsule parts of the first disintegrating body, and combine them to obtain a complete first disintegrating body;

[0080] (5) placing the second disintegrating body into the hollow part of the first disintegrating body to obtain a solid capsule body;

[0081] (6) Prepare a 6 wt % adhesive liquid, apply a layer evenly on the edge of the connection of the first disintegrating body of the capsule to form an adhesive layer, connect the first disintegrating bodies at both ends and dry them;

[0082] (7) The assembled solid capsule body is placed into a capsule coating with a thickness of 1 mm to obtain a pathfinder capsule.

[0083] Example 2

[0084] The preparation method is the same as that of Example 1, except that: in step (2), a press is used to control the capsule thickness to be 0.67 mm, so that the thickness ratio of the first capsule layer to the second capsule layer is 1:5.

[0085] Example 3

[0086] The preparation method is the same as that of Example 1, except that: in step (2), a press is used to control the capsule thickness to be 1.3 mm, so that the thickness ratio of the first capsule layer to the second capsule layer is 1:2.

[0087] Example 4

[0088] The preparation method is the same as that of Example 1, except that the total mass weighed in step (2) is 0.64 g, and the density of the first disintegrated body is 1.5 g / cm 3 .

[0089] Example 5

[0090] The preparation method is the same as that of Example 1, except that the total mass weighed in step (3) is 0.38 g, and the density of the first disintegrated body is 1 g / cm 3 .

[0091] Example 6

[0092] The preparation method is the same as that of Example 1, except that the capsule coating thickness in step (7) is 0.1 mm.

[0093] Comparative Example 1

[0094] The preparation method is the same as that of Example 1, except that in step (2), a press is used to control the capsule thickness to be 0.57 mm, so that the thickness ratio of the first capsule layer to the second capsule layer is 1:6.

[0095] Comparative Example 2

[0096] The preparation method is the same as that of Example 1, except that: in step (2), a press is used to control the capsule thickness to be 2 mm, so that the thickness ratio of the first capsule layer to the second capsule layer is 1:1.

[0097] Comparative Example 3

[0098] The preparation method is the same as that of Example 1, except that the total mass weighed in step (2) is 0.15 g, and the density of the first disintegrated body is 0.9 g / cm 3 .

[0099] Comparative Example 4

[0100] The preparation method is the same as that of Example 1, except that the total mass weighed in step (2) is 0.80 g, and the density of the first disintegrated body is 1.7 g / cm 3 .

[0101] Comparative Example 5

[0102] The preparation method is the same as that of Example 1, except that the capsule coating thickness in step (7) is 2 mm.

[0103] The disintegration time of the Pathfinder capsules prepared in Examples 1 to 6 and Comparative Examples 1 to 5 was tested according to the following method:

[0104] Prepare artificial gastric juice: take 16.4 mL of dilute hydrochloric acid, add 800 mL of water and 10 g of pepsin and dilute to 1000 mL; dilute hydrochloric acid is 234 mL of concentrated hydrochloric acid diluted to 1000 mL with water to obtain 9.5%~10.5% dilute hydrochloric acid;

[0105] Prepare artificial intestinal fluid: take 6.8g of potassium dihydrogen phosphate, add 500ml of water to dissolve it, and adjust the pH to 6.8 with 0.4% sodium hydroxide solution; take 10g of pancreatic enzyme (meeting the requirements of the pharmacopoeia), add appropriate amount of water to dissolve it; mix the two liquids, and dilute with water to 1000ml to obtain artificial intestinal fluid;

[0106] 500 ml of artificial gastric juice and artificial intestinal juice were put into the beaker of the disintegration instrument. The up and down swing of the disintegration instrument was used to replace gastrointestinal peristalsis. After the pathfinder capsule was swung in the artificial gastric juice for 2 hours, it was taken out and put into the artificial intestinal juice. The swing was continued, the disintegration of the capsule was observed, and the disintegration time was recorded. The results are shown in Table 1:

[0107] Table 1 Disintegration time data of the Pathfinder capsules prepared in Examples 1 to 6 and Comparative Examples 1 to 5

[0108]

[0109] According to the test results of Examples 1 to 3 and Comparative Examples 1 to 2, the disintegration time of the pathfinder capsule can be adjusted by adjusting the thickness ratio of the first capsule layer and the second capsule layer of the first disintegrating body;

[0110] According to the test results of Example 1, Examples 4-5 and Comparative Examples 3-4, the disintegration time of the pathfinder capsule can be adjusted by adjusting the density of the first disintegrating body;

[0111] According to the test results of Example 1, Example 6 and Comparative Example 5, the disintegration time of the Pathfinder capsule can be adjusted by adjusting the thickness of the capsule coating.

[0112] Example 7 Animal experiment using experimental pigs

[0113] Before the experiment, the experimental animals were prepared for intestinal tracts according to the method of capsule endoscopy: one end of the pathfinder capsule to be tested was fixed with a traction rope, and the fixed position was the non-isolation zone part of the outer surface of the pathfinder capsule coating, which was used to prevent the pathfinder capsule from being discharged from the experimental animal prematurely; during the experiment, the pathfinder capsule was delivered into the duodenum of the experimental animal by an electronic gastroscope, and the length of the traction rope was fixed so that the pathfinder capsule was always in the intestine of the experimental animal in an intact state. After the pathfinder capsule was delivered into the body of the experimental animal, a CT scan was performed on the experimental animal at 30 hours and 72 hours after the delivery of the capsule, respectively, to observe the disintegration of the pathfinder capsule in the experimental animal. The results of the animal experiment are shown in Table 2;

[0114] Table 2 Animal experiment results data table

[0115]

[0116] The above embodiments are only used to help understand the method and core idea of ​​the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.

[0117] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A soluble pathfinder capsule, comprising a first disintegrating body, a second disintegrating body and a capsule coating; the first disintegrating body is coated on the surface of the second disintegrating body, and the capsule coating is coated on the surface of the first disintegrating body; The first disintegrating body is composed of a first capsule layer near the capsule coating end and a second capsule layer far from the capsule coating end; The raw materials of the first capsule layer include: 50-65wt% anhydrous lactose, 20-40wt% starch, 2-10wt% talc, and 2-5wt% cross-linked polyvinyl pyrrolidone; The raw materials of the second capsule layer include: 60-70wt% anhydrous lactose, 10-15wt% starch, 2-10wt% talc, and 10-15wt% cross-linked polyvinyl pyrrolidone; The raw materials of the second disintegrating body include: 50-60wt% of anhydrous lactose, 5%-10wt% of starch, 2-5wt% of talc, 10-15wt% of tartaric acid, 10-15wt% of sodium bicarbonate, and 10-15wt% of barium sulfate.

2. The soluble pathfinder capsule according to claim 1, characterized in that: The thickness of the first disintegrating body is 2-4 mm, the thickness of the capsule coating is 0.1-1 mm, and the thickness of the second disintegrating body is 3-5 mm; the thickness ratio of the first capsule layer to the second capsule layer in the first disintegrating body is 1:(2-5).

3. The soluble pathfinder capsule according to claim 1, characterized in that: The density of the first disintegrated body is 1-1.5 g / cm 3 The density of the second disintegrated body is 1.2-1.6 g / cm 3 .

4. The soluble pathfinder capsule according to claim 1, characterized in that: The raw materials of the capsule coating include one or more of hydroxypropyl methylcellulose, gelatin and mannitol.

5. The soluble pathfinder capsule according to any one of claims 1 to 4, characterized in that: The first disintegrating body consists of two hollow half capsules.

6. The method for preparing the soluble pathfinder capsule according to claim 1 comprises the following steps: 50-65wt% of anhydrous lactose, 20-40wt% of starch, 2-10wt% of talc and 2-5wt% of cross-linked polyvinyl pyrrolidone are mixed and placed in a hollow mold, and pressed to obtain a first capsule layer; 60-70 wt% of anhydrous lactose, 10-15 wt% of starch, 2-10 wt% of talc and 10-15 wt% of cross-linked polyvinyl pyrrolidone are mixed and placed in a hollow mold, and pressed to obtain a second capsule layer; combining the first capsule layer and the second capsule layer to obtain a first disintegrated body; 50-60wt% of anhydrous lactose, 5%-10wt% of starch, 2-5wt% of talc, 10-15wt% of tartaric acid, 10-15wt% of sodium bicarbonate and 10-15wt% of barium sulfate are mixed and filled into a mold, and pressed to obtain a second disintegrating body; placing the second disintegrating body in the first disintegrating body, with the second capsule layer of the first disintegrating body close to the end of the second disintegrating body, to obtain a solid capsule body; The solid capsule body is placed in a capsule coating to obtain a soluble pathfinder capsule.

7. The preparation method according to claim 6, characterized in that: In the step of preparing the first capsule layer, the pressing pressure is 1-3T, and the holding time is 1-5min; In the step of preparing the second capsule layer, the pressing pressure is 1-3T, and the holding time is 1-5min; In the step of preparing the second disintegrated body, the pressing pressure is 1-3T, and the holding time is 1-5min.

8. Use of a soluble pathfinder capsule in determining intestinal obstruction, wherein the soluble pathfinder capsule is the soluble pathfinder capsule described in any one of claims 1 to 5 or the soluble pathfinder capsule prepared by the preparation method described in any one of claims 6 to 7.

9. The use according to claim 8, characterized in that: The application is specifically: Administer the soluble pathfinder capsule and observe whether the soluble pathfinder capsule is completely discharged within 30 hours; If so, capsule endoscopy is appropriate; If not, capsule endoscopy is not appropriate.

10. The use according to claim 8, characterized in that: The application is specifically: Administer the soluble pathfinder capsule and observe whether the soluble pathfinder capsule is completely discharged within 30 hours; If so, capsule endoscopy is appropriate; If it is uncertain whether the soluble pathfinder capsule has been expelled, an X-ray or CT examination should be performed ≤30 hours after the administration of the soluble pathfinder capsule. If the capsule is confirmed to be completely expelled based on the contrast image, capsule endoscopy is appropriate. If an X-ray or CT scan is performed when the soluble pathfinder capsule has been administered for more than 30 hours and it is determined based on the contrast images that the capsule has not been expelled, capsule endoscopy is not suitable.